Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development of a Prediction Platform for Adjuvant Treatment and Prognosis in Pancreatic Cancer Using Ex Vivo Analysis of Organoid Culture

NCT04736043 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT04736043
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04736043 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development of a Prediction Platform for Adjuvant Treatment and Prognosis in Pancreatic Cancer Using Ex Vivo Analysis of Organoid Culture
Lead sponsor
Samsung Medical Center
Phase
Observational
Overall status
Unknown status
Start date
January 31, 2021
Completion date
January 7, 2026
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer resectable